# Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)

> **NCT04993664** · NA · WITHDRAWN · sponsor: **University Medical Centre Ljubljana**

## Conditions studied

- Acute Coronary Syndrome
- Lipoproteinemia
- Inflammation
- Genetic Polymorphisms

## Interventions

- **DRUG:** Pelacarsen (TQJ230)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04993664
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative reason
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993664, "Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04993664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*